T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

Journal article

Publication Details

Author(s): Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML, Briet C, Luca F, Lapoirie M, Zoicas F, Simoneau I, Diallo AM, Muhammad A, Kelestimur F, Nazzari E, Garcia Centeno R, Webb SM, Nunes ML, Hana V, Pascal-Vigneron V, Ilovayskaya I, Nasybullina F, Achir S, Ferone D, Neggers SJCMM, Delemer B, Petit JM, Schoefl C, Raverot G, Goichot B, Rodien P, Corvilain B, Brue T, Schillo F, Tshibanda L, Maiter D, Bonneville JF, Beckers A
Journal: Endocrine-Related Cancer
Publication year: 2016
Volume: 23
Journal issue: 11
Pages range: 871-881
ISSN: 1351-0088


GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively; P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001, r = 0.22), IGF-1 (P < 0.0001, r = 0.14) and adenoma volume (P < 0.0001, r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with hormone reduction and tumor shrinkage in response to primary SSA treatment in acromegaly. This study supports its use as a generally available predictive tool at diagnosis that could help to guide subsequent treatment choices in acromegaly.

External institutions with authors

Assistance Publique Hopitaux de Marseille
Centre hospitalier régional et universitaire de Besançon (CHRU Besancon)
Centre hospitalier universitaire (CHU) d'Angers
Centre hospitalier universitaire (CHU) de Dijon Bourgogne
Centre Hospitalier Universitaire de Bordeaux / CHU Bordeaux
Centre hospitalier universitaire de Reims (CHU de Reims)
Centre Pierre-et-Marie-Curie
Chu De Nancy - Hôpitaux De Brabois
Erasmus University Rotterdam (EUR) / Erasmus Universiteit Rotterdam
Erciyes University / Erciyes Üniversitesi
Hôpitaux universitaires de Strasbourg (HUS) / University Hospital Strasbourg
Hospices Civils de Lyon (CHU)
Hospital de la Santa Creu i Sant Pau
Hospital General Universitario Gregorio Marañón
Kazan State Medical University (KSMU)
Klinikum Bamberg
Moscow Regional Research and Clinical Institute (MONIKI)
Université Catholique de Louvain (UCL)
Université libre de Bruxelles (ULB)
University of Genova / Università degli Studi di Genova
University of L'Aquila / Università degli Studi dell'Aquila
University of Liège (ULg) / Université de Liège
Univerzita Karlova v Praze / Charles University in Prague

How to cite

Potorac, I., Petrossians, P., Daly, A.F., Alexopoulou, O., Borot, S., Sahnoun-Fathallah, M.,... Beckers, A. (2016). T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 23(11), 871-881. https://dx.doi.org/10.1530/ERC-16-0356

Potorac, Iulia, et al. "T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly." Endocrine-Related Cancer 23.11 (2016): 871-881.


Last updated on 2018-09-10 at 02:27